1. Home
  2. MMA vs HIND Comparison

MMA vs HIND Comparison

Compare MMA & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMA

Alta Global Group Limited

HOLD

Current Price

$0.57

Market Cap

11.8M

Sector

N/A

ML Signal

HOLD

HIND

Vyome Holdings Inc.

N/A

Current Price

$2.16

Market Cap

13.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MMA
HIND
Founded
2013
2017
Country
Australia
United States
Employees
N/A
18
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
13.8M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
MMA
HIND
Price
$0.57
$2.16
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
209.1K
24.6K
Earning Date
05-20-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$1.75
52 Week High
$2.00
$12.87

Technical Indicators

Market Signals
Indicator
MMA
HIND
Relative Strength Index (RSI) 50.49 49.53
Support Level $0.35 $2.02
Resistance Level $0.58 $2.41
Average True Range (ATR) 0.05 0.17
MACD 0.00 0.02
Stochastic Oscillator 79.66 55.07

Price Performance

Historical Comparison
MMA
HIND

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: